|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Insulin Resistance
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
INSULIN RESISTANCE, SUSCEPTIBILITY TO
|
0.100 |
SusceptibilityMutation
|
disease |
CLINVAR |
|
|
|
|
Decreased waist to hip ratio
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, a striking increase in the expression of specific PTPases, LAR and PTP1B, was observed in 3 independently neu transformed cell lines and their derived tumors.
|
8097963 |
1993 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Specimens from 22 patients with tumors of borderline malignancy (11 serous and 11 mucinous tumors), 12 patients with benign tumors, and 16 patients with invasive ovarian carcinomas were evaluated for expression of epidermal growth factor receptor (EGFR), HER-2/neu, PTP1B, and p53 by immunohistochemical techniques.
|
8640675 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tyrosine phosphatase PTP1B was expressed by a similar fraction of benign (17%), borderline (27%), and malignant (19%) tumors.
|
8640675 |
1996 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Specimens from 22 patients with tumors of borderline malignancy (11 serous and 11 mucinous tumors), 12 patients with benign tumors, and 16 patients with invasive ovarian carcinomas were evaluated for expression of epidermal growth factor receptor (EGFR), HER-2/neu, PTP1B, and p53 by immunohistochemical techniques.
|
8640675 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We demonstrate that expression of either wild-type PTP1B or the substrate-trapping mutant form of the enzyme (PTP1B-D181A) in p210 bcr-abl-transformed Rat-1 fibroblasts diminished the ability of these cells to form colonies in soft agar, to grow in reduced serum, and to form tumors in nude mice.
|
9826659 |
1998 |
|
Myeloid Leukemia, Chronic
|
0.030 |
Biomarker
|
disease |
BEFREE |
These data suggest that PTP1B is a selective, endogenous inhibitor of p210 bcr-abl and is likely to be important in the pathogenesis of CML.
|
9826659 |
1998 |
|
Myeloid Leukemia, Chronic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In this study, we have demonstrated that expression of PTP1B is enhanced specifically in various cells expressing p210 bcr-abl, including a cell line derived from a patient with CML.
|
9566916 |
1998 |
|
Abetalipoproteinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results illustrate selectivity in the effects of PTPs in a cellular context and suggest that PTP1B may function as a specific, negative regulator of p210 bcr-abl signalling in vivo.
|
9566916 |
1998 |
|
Blast Phase
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, overexpression of PTP1B or treatment with CGP57148, a small molecule inhibitor of p210 bcr-abl, induced erythroid differentiation of K562 cells, a CML cell line derived from a patient in blast crisis.
|
9826659 |
1998 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The skeletal muscle activity of protein tyrosine phosphates 1B (PTP1B), a modulator of insulin and IGF-1 signaling, is reduced in obese nondiabetic subjects and in subjects with type 2 diabetes in comparison with leaner, nondiabetic controls.
|
10066387 |
1999 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, the protein tyrosine phosphatase PTP-1B has been shown to be a negative regulator of the insulin signaling pathway, suggesting that inhibitors of this enzyme may be beneficial in the treatment of type 2 diabetes.
|
10665340 |
1999 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mice lacking PTP-1B are resistant to both diabetes and obesity.
|
10665340 |
1999 |
|
Hyperinsulinism
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Since we have shown that the ratio of the insulin receptor splice variants is modulated by insulin in vitro and is related to insulin levels in vivo, we hypothesized that the relative ratios of the alternatively spliced PTP1B mRNA might also vary in humans in proportion to the degree of hyperinsulinemia.
|
10066387 |
1999 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice lacking PTP-1B are resistant to both diabetes and obesity.
|
10665340 |
1999 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice lacking PTP-1B are resistant to both diabetes and obesity.
|
10665340 |
1999 |
|
Insulin Resistance
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.
|
10744717 |
2000 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
CTD_human |
Recent studies have shown increased insulin sensitivity and resistance to obesity in PTP1B knockout mice, thus pointing to this enzyme as a potential drug target in diabetes.
|
10744717 |
2000 |
|
Insulin Sensitivity
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Recent studies have shown increased insulin sensitivity and resistance to obesity in PTP1B knockout mice, thus pointing to this enzyme as a potential drug target in diabetes.
|
10744717 |
2000 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Examination of several human breast cancer cell lines with increased c-Src activity showed elevated levels of PTP1B protein relative to normal control breast cells.
|
11007774 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The regions defined by the AIB1 and PTPN1 genes (at 20q12 and 20q13.1, respectively) were amplified in 25% and 29% of the sporadic tumors, also without simultaneous coamplification of other regions.
|
10815905 |
2000 |